JP2023508975A - ガンマ－ヒドロキシ酪酸塩（ｇｈｂ）投薬 - Google Patents

ガンマ－ヒドロキシ酪酸塩（ｇｈｂ）投薬 Download PDF

Info

Publication number
JP2023508975A
JP2023508975A JP2022539046A JP2022539046A JP2023508975A JP 2023508975 A JP2023508975 A JP 2023508975A JP 2022539046 A JP2022539046 A JP 2022539046A JP 2022539046 A JP2022539046 A JP 2022539046A JP 2023508975 A JP2023508975 A JP 2023508975A
Authority
JP
Japan
Prior art keywords
oxybate
mixed salt
patient
administered
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508975A5 (https=
Inventor
スコビエランダ，フランク
Original Assignee
ジャズ ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ ファーマシューティカルズ アイルランド リミテッド filed Critical ジャズ ファーマシューティカルズ アイルランド リミテッド
Publication of JP2023508975A publication Critical patent/JP2023508975A/ja
Publication of JP2023508975A5 publication Critical patent/JP2023508975A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2022539046A 2019-12-24 2020-12-22 ガンマ－ヒドロキシ酪酸塩（ｇｈｂ）投薬 Pending JP2023508975A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US62/953,288 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US62/993,372 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US63/000,547 2020-03-27
US202063052676P 2020-07-16 2020-07-16
US63/052,676 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (2)

Publication Number Publication Date
JP2023508975A true JP2023508975A (ja) 2023-03-06
JP2023508975A5 JP2023508975A5 (https=) 2023-12-22

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539046A Pending JP2023508975A (ja) 2019-12-24 2020-12-22 ガンマ－ヒドロキシ酪酸塩（ｇｈｂ）投薬

Country Status (14)

Country Link
US (3) US20210186907A1 (https=)
EP (1) EP4081204A1 (https=)
JP (1) JP2023508975A (https=)
KR (1) KR20220119429A (https=)
CN (1) CN115209885A (https=)
AU (1) AU2020414694A1 (https=)
BR (1) BR112022012594A2 (https=)
CA (1) CA3162974A1 (https=)
CL (1) CL2022001743A1 (https=)
CO (1) CO2022010330A2 (https=)
IL (1) IL294176A (https=)
MX (1) MX2022007968A (https=)
TW (1) TW202135790A (https=)
WO (1) WO2021133778A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525480A (ja) * 2010-05-04 2013-06-20 ジャズ、ファーマシューティカルズ、インコーポレイテッド γ−ヒドロキシ酪酸塩の即時放出製剤および剤形
JP2016503762A (ja) * 2012-12-14 2016-02-08 ジャズ ファーマシューティカルス アイルランド リミテッド ガンマ‐ヒドロキシ酪酸塩組成物及び疾患の治療のためのその使用
JP2016510031A (ja) * 2013-03-01 2016-04-04 ジャズ ファーマシューティカルス アイルランド リミテッド モノカルボン酸塩若しくはエステル輸送体を伴うγ−ヒドロキシ酪酸塩若しくはエステルの投与
WO2018167303A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525480A (ja) * 2010-05-04 2013-06-20 ジャズ、ファーマシューティカルズ、インコーポレイテッド γ−ヒドロキシ酪酸塩の即時放出製剤および剤形
JP2016503762A (ja) * 2012-12-14 2016-02-08 ジャズ ファーマシューティカルス アイルランド リミテッド ガンマ‐ヒドロキシ酪酸塩組成物及び疾患の治療のためのその使用
JP2016510031A (ja) * 2013-03-01 2016-04-04 ジャズ ファーマシューティカルス アイルランド リミテッド モノカルボン酸塩若しくはエステル輸送体を伴うγ−ヒドロキシ酪酸塩若しくはエステルの投与
WO2018167303A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
BR112022012594A2 (pt) 2022-09-06
TW202135790A (zh) 2021-10-01
IL294176A (en) 2022-08-01
CN115209885A (zh) 2022-10-18
WO2021133778A1 (en) 2021-07-01
CA3162974A1 (en) 2021-07-01
US20210186907A1 (en) 2021-06-24
CO2022010330A2 (es) 2022-10-21
AU2020414694A1 (en) 2022-08-18
US20210361601A1 (en) 2021-11-25
EP4081204A1 (en) 2022-11-02
MX2022007968A (es) 2022-09-02
CL2022001743A1 (es) 2023-02-10
US20240285560A1 (en) 2024-08-29
KR20220119429A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
JP2023508975A (ja) ガンマ－ヒドロキシ酪酸塩（ｇｈｂ）投薬
US20250073192A1 (en) Methods of treating idiopathic hypersomnia
JP2023036649A (ja) γ－ヒドロキシブチレート組成物及び障害の治療のためのそれらの使用
US20190269671A1 (en) Method for treating tumour, pharmaceutical composition and medicinal kit
AU2011285928B2 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
JP5185488B2 (ja) ２−（４−イソブチルフェニル）プロピオン酸の医薬組成物
RS62329B1 (sr) Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
US20230000866A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
CN113557022A (zh) 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
JP2019521185A (ja) レボチロキシン溶液の製造方法
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
AU2016353350A1 (en) Formulation of L-ornithine phenylacetate
WO2008025781A1 (en) Bifeprunox doses for treating schizophrenia
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
US12582622B2 (en) Sodium oxybate to treat idiopathic hypersomnia
CN119868549A (zh) 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
WO2012150607A2 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
JP7709202B2 (ja) 睡眠障害を伴うｃｎｓ障害の治療
JP2024541770A (ja) 神経障害の治療方法
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
CN120939018A (zh) 一种jak激酶抑制剂的药物组合物
WO2026050628A1 (en) Tablet formulations
EP4637706A1 (en) Liquid pharmaceutical formulations of tafamidis
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
NZ737544A (en) Micronized compound a, compositions and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250514